ONCO Onconetix, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1782107 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-51.3%
TTM net income YoY76.9%
TTM EPS YoY216.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin80.4%
Operating margin-2,525.0%
Net margin-1,578.8%
FCF margin—
EBITDA margin-2,522.7%
Returns
ROE-105.2%
ROA-57.4%
ROIC (approx.)-195.9%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets18.0%
Debt / equity0.00x
Current ratio2.21x
Interest coverage-52.44x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $102,884 | $17,120 | $21,457 | $303,596 | $303,651 | $106,494 | $101,630 | $711,976 |
| Cost of revenue | $24,718 | $12,817 | $23,112 | $55,912 | $34,757 | $35,991 | $55,798 | $52,008 |
| Gross profit | $78,166 | $4,303 | -$1,655 | $247,684 | $268,894 | $70,503 | $45,832 | $659,968 |
| R&D expense | — | — | — | — | — | — | $24,455 | -$290 |
| SG&A expense | $1.48M | $2.25M | $2.04M | $1.50M | $2.34M | $1.52M | $1.67M | $2.63M |
| Operating income | -$1.41M | -$2.73M | -$10.23M | -$1.28M | -$2.07M | -$1.94M | -$12.57M | -$29.15M |
| Interest expense | $3,246 | $4,389 | $2,244 | $4,247 | $300,069 | $223,097 | $223,592 | $339,188 |
| Pretax income | -$31.63M | -$2.87M | -$4.21M | $5.67M | -$8.78M | -$2.37M | -$8.55M | -$30.36M |
| Income tax | — | — | — | — | — | — | — | -$917,997 |
| Net income | -$31.63M | -$2.87M | -$4.21M | $5.67M | -$8.78M | -$2.37M | -$8.55M | -$29.44M |
| EBITDA | -$1.40M | -$2.73M | -$10.22M | -$1.28M | -$2.07M | -$1.93M | -$12.57M | -$29.03M |
| EPS (basic) | -76.01 | -1.28 | -6.71 | — | -3,124.76 | -237.91 | -227.25 | — |
| EPS (diluted) | -76.01 | -1.28 | -6.71 | — | -3,124.76 | -237.91 | -227.25 | — |
| Weighted avg. shares (diluted) | 416,117 | 2.24M | 628,528 | — | 2,811 | 11,353 | 42,755 | — |
| Banking | ||||||||
| Deposits | — | — | — | — | — | — | — | $3.50M |
| Balance sheet | ||||||||
| Cash & equivalents | $2.74M | $5.94M | $3.72M | $5.22M | $836,556 | $283,515 | $1.58M | $646,500 |
| Receivables | $103,421 | $2,351 | $43,725 | $296,866 | $2,552 | $12,156 | $16,293 | $25,717 |
| Inventory | $192,644 | $210,448 | $137,642 | $149,961 | $151,556 | $153,072 | $155,660 | $64,079 |
| Current assets | $5.94M | $6.52M | $4.33M | $6.07M | $1.30M | $930,531 | $2.42M | $950,267 |
| PP&E, net | $25,297 | $28,655 | $31,533 | $37,085 | $40,388 | $43,809 | $55,805 | $62,896 |
| Goodwill | $9.33M | $9.62M | $10.20M | $18.55M | $18.18M | $18.12M | $16.21M | $18.55M |
| Total assets | $15.55M | $16.43M | $14.83M | $24.93M | $19.68M | $19.12M | $18.78M | $28.18M |
| Current liabilities | $4.03M | $2.94M | $3.07M | $9.14M | $16.30M | $12.69M | $14.04M | $18.29M |
| Total liabilities | $4.04M | $2.96M | $3.08M | $9.16M | $16.30M | $12.77M | $14.26M | $18.57M |
| Shareholders' equity | -$17.29M | $13.47M | $11.75M | $15.76M | $3.37M | $5.91M | $3.99M | $8.54M |
| Shares outstanding | — | 3.79M | 2.76M | 31,198 | 1.56M | 1.01M | 36.76M | 138,270 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.72M | -$1.92M | -$2.12M | -$3.09M | -$3.18M | -$1.41M | -$2.00M | -$917,647 |
| Capital expenditure | — | — | — | — | — | — | — | $3,874 |
| Free cash flow | — | — | — | — | — | — | — | -$921,521 |
| Investing cash flow | — | — | — | — | — | — | — | -$3,874 |
| Financing cash flow | $1.08M | $4.17M | $631,788 | $6.55M | $4.29M | $744,574 | $2.87M | $1.30M |
| Depreciation & amortization | $2,552 | $2,632 | $5,398 | $3,336 | $3,387 | $3,699 | $4,748 | $119,299 |
| Stock-based compensation | $0 | $7,359 | $22,305 | $4,234 | $9,795 | $30,982 | $29,256 | $340,425 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.